Log in to Thinknum

Interested in Thinknum?

Request a demo
CH

Chiasma

- NASDAQ:CHMA
Last Updated 2019-05-24

LinkedIn Profile

Access Chiasma historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Ticker Sector Ticker Industry
nasdaq:chma 719282 May 25th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 25th, 2019 02:00PM May 25th, 2019 02:00PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 24th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 23rd, 2019 10:17PM May 23rd, 2019 10:17PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 23rd, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 23rd, 2019 10:46AM May 23rd, 2019 10:46AM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 22nd, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 22nd, 2019 02:29PM May 22nd, 2019 02:29PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 21st, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 21st, 2019 10:24AM May 21st, 2019 10:24AM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 20th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 19th, 2019 10:15PM May 19th, 2019 10:15PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 19th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 19th, 2019 03:37PM May 19th, 2019 03:37PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 18th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 18th, 2019 10:37AM May 18th, 2019 10:37AM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 17th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 17th, 2019 04:10PM May 17th, 2019 04:10PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology
nasdaq:chma 719282 May 16th, 2019 12:00AM Chiasma 1.9K 27.00 Open Biotechnology May 15th, 2019 10:15PM May 15th, 2019 10:15PM Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection. The company’s lead product candidate is octreotide capsules for the orphan condition acromegaly. Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery using the company’s TPE® technology. Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Open Open 275 Wyman Street, Suite 250 Waltham MA US 02451 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.